228 related articles for article (PubMed ID: 25519159)
1. Bivalirudin for acute coronary syndromes: premises, promises and doubts.
Capodanno D; De Caterina R
Thromb Haemost; 2015 Apr; 113(4):698-707. PubMed ID: 25519159
[TBL] [Abstract][Full Text] [Related]
2. Bivalirudin in percutaneous coronary intervention, is it the anticoagulant of choice?
Mahmoud A; Saad M; Elgendy AY; Abuzaid A; Elgendy IY
Cardiovasc Ther; 2015 Aug; 33(4):227-35. PubMed ID: 25879426
[TBL] [Abstract][Full Text] [Related]
3. Cost analysis of bivalirudin versus reference anticoagulants without GP IIb/IIIa inhibitors in patients undergoing percutaneous coronary intervention for acute coronary syndrome in routine clinical practice. Pompidou registry.
Puymirat E; Cohen S; Védrenne G; Caruba T; Sabatier B; Danchin N; Durand E
Ann Cardiol Angeiol (Paris); 2013 Apr; 62(2):89-94. PubMed ID: 23245394
[TBL] [Abstract][Full Text] [Related]
4. The clinical and economic impact of bivalirudin for percutaneous coronary intervention.
Malik N; Gershlick AH
Expert Rev Pharmacoecon Outcomes Res; 2013 Dec; 13(6):699-706. PubMed ID: 24219045
[TBL] [Abstract][Full Text] [Related]
5. Bivalirudin versus heparin plus a glycoprotein IIb/IIIa inhibitor in patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention after clopidogrel pretreatment: pooled analysis from the ACUITY and ISAR-REACT 4 trials.
Ndrepepa G; Neumann FJ; Deliargyris EN; Mehran R; Mehilli J; Ferenc M; Schulz S; Schömig A; Kastrati A; Stone GW
Circ Cardiovasc Interv; 2012 Oct; 5(5):705-12. PubMed ID: 23048052
[TBL] [Abstract][Full Text] [Related]
6. Economic evaluation of bivalirudin with or without glycoprotein IIb/IIIa inhibition versus heparin with routine glycoprotein IIb/IIIa inhibition for early invasive management of acute coronary syndromes.
Pinto DS; Stone GW; Shi C; Dunn ES; Reynolds MR; York M; Walczak J; Berezin RH; Mehran R; McLaurin BT; Cox DA; Ohman EM; Lincoff AM; Cohen DJ;
J Am Coll Cardiol; 2008 Nov; 52(22):1758-68. PubMed ID: 19022155
[TBL] [Abstract][Full Text] [Related]
7. Outcomes of patients with acute coronary syndromes who are treated with bivalirudin during percutaneous coronary intervention: an analysis from the Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE-2) trial.
Rajagopal V; Lincoff AM; Cohen DJ; Gurm HS; Hu T; Desmet WJ; Kleiman NS; Bittl JA; Feit F; Topol EJ
Am Heart J; 2006 Jul; 152(1):149-54. PubMed ID: 16824845
[TBL] [Abstract][Full Text] [Related]
8. Influence of timing of clopidogrel treatment on the efficacy and safety of bivalirudin in patients with non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention: an analysis of the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial.
Lincoff AM; Steinhubl SR; Manoukian SV; Chew D; Pollack CV; Feit F; Ware JH; Bertrand ME; Ohman EM; Desmet W; Cox DA; Mehran R; Stone GW;
JACC Cardiovasc Interv; 2008 Dec; 1(6):639-48. PubMed ID: 19463378
[TBL] [Abstract][Full Text] [Related]
9. Combined Use of Bivalirudin and Radial Access in Acute Coronary Syndromes Is Not Superior to the Use of Either One Separately: Meta-Analysis of Randomized Controlled Trials.
Mina GS; Gobrial GF; Modi K; Dominic P
JACC Cardiovasc Interv; 2016 Aug; 9(15):1523-31. PubMed ID: 27491601
[TBL] [Abstract][Full Text] [Related]
10. Bivalirudin for primary percutaneous coronary interventions: outcome assessment in the Ottawa STEMI registry.
Hibbert B; MacDougall A; Labinaz M; O'Brien ER; So DY; Dick A; Glover C; Froeschl M; Marquis JF; Wells GA; Blondeau M; Le May MR
Circ Cardiovasc Interv; 2012 Dec; 5(6):805-12. PubMed ID: 23149331
[TBL] [Abstract][Full Text] [Related]
11. Bivalirudin is associated with improved clinical and economic outcomes in heart failure patients undergoing percutaneous coronary intervention: Results from an observational database.
Pinto DS; Kohli P; Fan W; Kirtane AJ; Kociol RD; Meduri C; Deliargyris EN; Prats J; Reynolds MR; Stone GW; Michael Gibson C
Catheter Cardiovasc Interv; 2016 Feb; 87(3):363-73. PubMed ID: 26011467
[TBL] [Abstract][Full Text] [Related]
12. The bivalirudin paradox: high evidence, low use.
De Servi S; Mariani G; Mariani M; D'Urbano M
J Cardiovasc Med (Hagerstown); 2013 May; 14(5):334-41. PubMed ID: 23442811
[TBL] [Abstract][Full Text] [Related]
13. Bivalirudin: a direct thrombin inhibitor.
Gladwell TD
Clin Ther; 2002 Jan; 24(1):38-58. PubMed ID: 11833835
[TBL] [Abstract][Full Text] [Related]
14. Bivalirudin use and one-month outcome in the context of contemporary antiplatelet treatment: insights from the Greek Antiplatelet Registry.
Alexopoulos D; Xanthopoulou I; Deftereos S; Sitafidis G; Kanakakis I; Hamilos M; Karayannis G; Angelidis C; Stavrou K; Vavuranakis M; Goudevenos JA; Stefanadis C;
Cardiovasc Ther; 2014 Jun; 32(3):120-6. PubMed ID: 24512682
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitor in the treatment of non-ST-segment elevation acute coronary syndromes.
Schwenkglenks M; Brazier JE; Szucs TD; Fox KA
Value Health; 2011 Jan; 14(1):24-33. PubMed ID: 21211483
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of bivalirudin with and without glycoprotein IIb/IIIa inhibitors in patients with acute coronary syndromes undergoing percutaneous coronary intervention 1-year results from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial.
White HD; Ohman EM; Lincoff AM; Bertrand ME; Colombo A; McLaurin BT; Cox DA; Pocock SJ; Ware JA; Manoukian SV; Lansky AJ; Mehran R; Moses JW; Stone GW
J Am Coll Cardiol; 2008 Sep; 52(10):807-14. PubMed ID: 18755342
[TBL] [Abstract][Full Text] [Related]
17. Follow the data: bivalirudin (and not heparin alone) during percutaneous coronary intervention provides the best clinical outcomes.
Stone GW; Mehran R; Steg PG
JACC Cardiovasc Interv; 2015 Jan; 8(1 Pt B):225-227. PubMed ID: 25616930
[No Abstract] [Full Text] [Related]
18. Pharmacoeconomics of anticoagulants in acute coronary syndrome and percutaneous coronary intervention.
Huston SA; Hawkins D
Curr Pharm Des; 2008; 14(12):1197-204. PubMed ID: 18473867
[TBL] [Abstract][Full Text] [Related]
19. Economic impact of switching to bivalirudin for a primary percutaneous coronary intervention in a US hospital.
Olchanski N; Slawsky KA; Plent S; Kado C; Cyr PL
Hosp Pract (1995); 2010 Nov; 38(4):138-46. PubMed ID: 21068538
[TBL] [Abstract][Full Text] [Related]
20. Bivalirudin: a pharmacoeconomic profile of its use in patients with acute coronary syndromes.
Lyseng-Williamson KA
Pharmacoeconomics; 2011 Apr; 29(4):343-59. PubMed ID: 21395353
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
